Robert W. Alexander, MD, DMD, FICS is the Principal Investigator, and his office is recruiting patients for enrollment in the trial.
More information about the protocols and merits of the study, as well as the research that has led to the FDA's oversight of a patient trial, is available on the San Diego Academy of Regenerative Therapies (SDARTS.com) Online Learning Platform.
The Panel discussion recorded on October 1, 2020, features Dr. Alexander and Dr. Ramon Llull, MD, Ph.D., a research colleague who has done extensive studies on the use of cellular Stromal Vascular Fraction.
Tulip Medical is a subsidiary of SDARTs.
Patients considering participation in this clinical trial should email Dr. Alexander at irbtrials@gmail.com.
Watch the Panel Discussion Webinar with Dr. Alexander and Dr. Ramon Llull.
Read Dr. Alexander's newest article detailing the diagnostic and treatment protocol for this ground-breaking clinical trial in Stem Cell Research.
Read Dr. Llull's latest article characterizing adipose tissue's regenerative capabilities in the Journal of Plastic and Reconstructive Surgery.
Tulip Medical develops and markets medical devices and systems for using adipose tissue for plastic surgery, dermatology, regenerative medicine, and anti-aging patient applications.
Tulip holds numerous patents on medical devices and methods designed to help medical practitioners harness and deliver the benefits of fat to millions of patients.
Creo Medical secures FDA clearance for SpydrBlade Flex in US market
Tissue Regenix secures CE and UKCA certifications for OrthoPure XT
Terumo Corporation expands stroke portfolio in EMEA with SOFIA Flow 88 catheter launch
Crossject advances ZENEO manufacturing with scalable aseptic filling module ahead of product rollout
Mindray unveils BeneVision V Series at Euroanaesthesia 2025, advancing precision monitoring
Unicon Pharma and VRR Life Sciences partner support digital transformation in life sciences
Median Technologies submits 510(k) application for eyonis LCS lung cancer screening software
Tristel secures FDA clearance for Ophthalmic Disinfectant Tristel OPH